DAY101 In Gliomas and Other Tumors

计划入组 44 人 · 首次发布于 2018 年 2 月 12 日

Evaluation of Pathway Modulation by Raf, MEK, & Kinase Inhibitors

计划入组 45 人 · 首次发布于 2017 年 6 月 5 日

Study of MEK162 for Children With Low-Grade Gliomas

计划入组 105 人 · 首次发布于 2014 年 11 月 7 日

CKBP-002

ERK-CLIPTAC

RAF-709

Pathway Therapeutics, Inc.

United States

Kura Oncology

United States

Erasca

United States

Neurofibromatoses Pipeline Shows Strong Activity with 12+ Therapies in Development Across Multiple Clinical Stages

European Commission Approves First MEK Inhibitor for NF1-Associated Plexiform Neurofibromas in Adults and Children

Servier and Black Diamond Therapeutics Forge $780M Global Licensing Deal for Novel RAF/RAS Cancer Therapy